Evaxion Biotech announces data for CMV vaccine program EVX-V1

Evaxion is successfully advancing its novel multi-component cytomegalovirus, CMV, vaccine program, EVX-V1, with new data demonstrating protective effects of lead antigens in the program. With our AI-Immunology platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field. These previously unexplored CMV-antigens induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal viral infection models. These are significant discoveries since very few protective CMV-antigens have been identified despite decades of intensive research. The new findings add to earlier data demonstrating that Evaxion’s proprietary AI-optimized pre-fusion glycoprotein B antigen effectively neutralizes CMV. This enhanced gB antigen constitutes a key component of EVX-V1, which combines AI-discovered antigens with AI-optimized conventional antigens to attack the virus from multiple, complementary angles. This broader multi-targeted strategy is expected to strengthen the protective potential of the future vaccine.